Search Results for "ciclesonide"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for ciclesonide. Results 1 to 10 of 14 total matches.
Ciclesonide (Omnaris) for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • May 05, 2008 (Issue 1285)
Ciclesonide (Omnaris) for Allergic Rhinitis ...
Ciclesonide (Omnaris - Sepracor/Nycomed), a once daily corticosteroid nasal spray, is now available for treatment of seasonal allergic rhinitis (SAR) in adults and children ≥6 years old and for perennial allergic rhinitis (PAR) in those ≥12 years old. An orally inhaled formulation of ciclesonide (Alvesco) was recently approved by the FDA for maintenance treatment of asthma, and will be reviewed in a future issue of The Medical Letter
Ciclesonide (Alvesco) - A New Inhaled Corticosteroid for Asthma
The Medical Letter on Drugs and Therapeutics • Sep 22, 2008 (Issue 1295)
Ciclesonide (Alvesco) - A New Inhaled Corticosteroid for Asthma ...
The FDA has approved the marketing of the corticosteroid ciclesonide (Alvesco - Sepracor) in a hydrofluoroalkane (HFA) metered-dose inhaler formulation for maintenance treatment of asthma in patients >12 years old. Ciclesonide is also available in the US as a nasal spray for allergic rhinitis (Omnaris), and has been available for asthma in Europe since 2003.
In Brief: Two Intranasal Corticosteroid HFA Aerosols for Allergic Rhinitis (online only)
The Medical Letter on Drugs and Therapeutics • Oct 15, 2012 (Issue 1401)
(Qnasl – Teva Respiratory) and
ciclesonide (Zetonna – Sunovion) for once-daily treatment
of seasonal ...
The FDA has approved 2 intranasal HFA (hydrofluoroalkane) aerosols of the corticosteroids beclomethasone dipropionate (Qnasl – Teva Respiratory) and ciclesonide (Zetonna – Sunovion) for once-daily treatment of seasonal and perennial allergic rhinitis. They are the first HFA nasal steroids to become available in the US (HFA propellants do not deplete the ozone layer). Both drugs are already available for these indications as aqueous nasal sprays. Aqueous ("wet") formulations can cause adverse effects such as postnasal drip, moist feeling in the nose, strong odor, and bitter aftertaste,...
An OTC Corticosteroid Nasal Spray for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • Nov 11, 2013 (Issue 1429)
potent) intranasal corticosteroids
such as ciclesonide (Omnaris, Zetonna), fluticasone
furoate ...
The FDA has approved the over-the-counter (OTC)
sale of Nasacort Allergy 24HR (Sanofi), a triamcinolone
acetonide nasal spray previously available only
by prescription as Nasacort AQ. The OTC product,
which is scheduled to be marketed in the spring of
2014, will be the first corticosteroid nasal spray that
can be purchased without a prescription in the US.
Nasacort Allergy 24HR is approved for use in patients
≥2 years old with nasal allergy symptoms.
Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis (online only)
The Medical Letter on Drugs and Therapeutics • Mar 31, 2025 (Issue 1725)
Ciclesonide –
Omnaris (Covis) Metered-dose pump spray
(50 mcg/spray)
120 sprays (12.5 g bottle)
Rx ≥6 yrs ...
View the Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis
Med Lett Drugs Ther. 2025 Mar 31;67(1725):e58-63 doi:10.58347/tml.2025.1725c | Show Introduction Hide Introduction
Azelastine/Fluticasone Propionate (Dymista) for Seasonal Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • Oct 29, 2012 (Issue 1402)
nostril 1x/d
Ciclesonide – Omnaris Metered-dose pump spray 2 sprays per >6 yrs4: 2 sprays per 114.04 ...
The FDA has approved a nasal spray fixed-dose combination (Dymista – Meda) of the H1-antihistamine azelastine (Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate (Flonase, and generics) for treatment of seasonal allergic rhinitis (SAR) in patients ≥12 years old who need both medications for symptomatic relief. It is the first nasal spray to be approved in the US that contains both an H1-antihistamine and a corticosteroid.
Fluticasone Furoate (Arnuity Ellipta) for Asthma
The Medical Letter on Drugs and Therapeutics • May 25, 2015 (Issue 1469)
(AstraZeneca) 90, 180 mcg/inh bid
Ciclesonide – HFA MDI (60 inh/unit) 80-320 mcg bid ≥12 yrs: 80-320 mcg ...
The FDA has approved Arnuity Ellipta (GSK), a single-agent
inhaler containing the corticosteroid fluticasone
furoate, for once-daily maintenance treatment of
asthma in patients ≥12 years old. Fluticasone furoate
is also available in combination with the long-acting
beta2-agonist vilanterol as Breo Ellipta for treatment
of asthma and COPD.
Table: Correct Use of Inhalers for COPD (online only)
The Medical Letter on Drugs and Therapeutics • Sep 07, 2020 (Issue 1606)
):
www.accessdata.fda.gov/drugsatfda_docs/label/2013/021247s008lbl.pdf
Alvesco (ciclesonide):
www.accessdata.fda.gov ...
View the Table: Correct Use of Inhalers for COPD
Comparison Chart: Some Inhaled Drugs for Treatment of Asthma (online only)
The Medical Letter on Drugs and Therapeutics • Nov 25, 2024 (Issue 1716)
: 0.25 mg bid or 0.5 mg
once/d or bid or 1 mg once/d9
872.0012
753.0012
Ciclesonide – Alvesco ...
View the Comparison Chart: Some Inhaled Drugs for Treatment of Asthma
Med Lett Drugs Ther. 2024 Nov 25;66(1716):e192-5 doi:10.58347/tml.2024.1716b | Show Introduction Hide Introduction
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • Nov 25, 2024 (Issue 1716)
.
Ciclesonide and beclomethasone dipropionate,
prodrugs that are activated in the lungs, are less likely ...
The goal of asthma treatment is to control symptoms,
prevent exacerbations, and maintain normal lung
function. Management of acute exacerbations in the
emergency department is not discussed here.
Med Lett Drugs Ther. 2024 Nov 25;66(1716):185-92 doi:10.58347/tml.2024.1716a | Show Introduction Hide Introduction